Status:
COMPLETED
The Metformin in Coronary Artery Bypass Graft (CABG) (MetCAB) Trial
Lead Sponsor:
Radboud University Medical Center
Conditions:
Cardiovascular Disease
Ischemic Heart Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Rationale: In patients with a myocardial infarction, occlusion of a coronary artery induces myocardial ischemia and cell death. If untreated, the area of myocardium exposed to this interruption in bl...
Eligibility Criteria
Inclusion
- Acceptation for CABG with or without concomitant valve surgery
- Informed consent
- Age ≥ 18 years
Exclusion
- Diabetes mellitus
- Renal dysfunction (MDRD \< 60 ml/min)
- Elevated liver enzymes (ALAT \> 3 times upper limit of reference range)
- Treatment with dipyridamole or xanthine derivatives
- Recent myocardial infarction (\<2 weeks before inclusion)
- Off-pump surgery
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01438723
Start Date
November 1 2011
End Date
July 1 2014
Last Update
July 29 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RUNMC
Nijmegen, Gelderland, Netherlands